Facebook Linkedin Mail Twitter Youtube
  • Home
  • Research
  • Blog
  • TRIPS Flexibilities Database
  • Other Resources
    • Covid-19
    • Tools
      • Introduction
      • Model Government Use Licences
      • Model Uses of Paragraph 7 or “LDC Waiver”
      • Special Compulsory Licences for Export of Medicines
      • Options for Regional Economic Communities
      • Voluntary Licences
    • Useful Links
  • About
Search
Menu

Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

Medicines Law & PolicyResearch and resources on intellectual property and health
Twitter
Linkedin
Facebook
Medicines Law & Policy
Research and resources
on intellectual property and health.
Contact Us
Subscribe

Subscribe to our newsletter and never miss a post!

* indicates required

Medicines Law & Policy will use the information you provide to keep you up-to-date when we post new research and insight. You can change your mind about receiving our newsletter any time by clicking the unsubscribe link in the footer of any email you receive from us. We will treat your information with respect. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Menu

Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

  • Home
  • Research
  • Blog
  • TRIPS Flexibilities Database
  • Other Resources
    • Covid-19
    • Tools
      • Introduction
      • Model Government Use Licences
      • Model Uses of Paragraph 7 or “LDC Waiver”
      • Special Compulsory Licences for Export of Medicines
      • Options for Regional Economic Communities
      • Voluntary Licences
    • Useful Links
  • About

Kaitlin Mara

12 POSTS 0 COMMENTS
Kaitlin Mara, MSc, has been writing about international intellectual property and innovation policy for a decade.

The Waiver that Wasn’t: Is the pharma lobby responsible?

Kaitlin Mara - November 14, 2022

With technology transfer, 120 companies in low- and middle-income countries could manufacture mRNA vaccines

Kaitlin Mara - February 15, 2022

Landmark decision by the World Health Assembly to start negotiations for a pandemic treaty

Kaitlin Mara - December 1, 2021

The WHO Covid-19 Technology Access Pool signs first licence agreement; will hopefully be a...

Kaitlin Mara - November 23, 2021

WHO’s Essential Medicines Committee takes aim at rising prices, adds new treatments for cancer...

Kaitlin Mara - October 6, 2021

Independent Panel for Pandemic Preparedness and Response: Uneven access to vaccination is pre-eminent problem

Kaitlin Mara - May 12, 2021

Decision on intellectual property waiver over Covid technology on hold till 2021; what are...

Kaitlin Mara - December 18, 2020

Ellen ‘t Hoen named one of the “50 Most Influential People in IP”

Kaitlin Mara - December 2, 2020

Human Rights Watch: All governments should endorse the WHO C-TAP Solidarity Call to Action

Kaitlin Mara - October 30, 2020

Invitation: 14 May 2020 – The WHO Covid-19 Technology Pool: The solution to ensure...

Kaitlin Mara - May 12, 2020
12Page 1 of 2

Medicines Law & Policy

Facebook
Linkedin
Twitter

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

  • Home
  • Research
  • Blog
  • TRIPS Flexibilities Database
  • Tools
  • Covid-19
  • Useful Links
  • About
  • TRIPS Flexibilities Database
  • Other resources

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).

* indicates required






Medicines Law & Policy will use the information you provide to keep you up-to-date when we post new research and insight. You can change your mind about receiving our newsletter any time by clicking the unsubscribe link in the footer of any email you receive from us. We will treat your information with respect. By clicking below, you agree that we may process your information in accordance with these terms. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

 
 

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.